Suppr超能文献

肝移植治疗肝细胞癌时,术中输注红细胞和新鲜冰冻血浆的重要性。

Importance of Intraoperative Transfusions of Packed Red Blood Cells and Fresh Frozen Plasma in Liver Transplantation for Hepatocellular Cancer.

机构信息

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Department of General, Vascular and Oncological Surgery, Medical University of Warsaw, Warsaw, Poland.

出版信息

Ann Transplant. 2020 Oct 9;25:e923665. doi: 10.12659/AOT.923665.

Abstract

BACKGROUND The impact of packed red blood cells (PRBCs) and fresh frozen plasma (FFP) transfusions in patients with hepatocellular cancer (HCC) undergoing liver transplantation has rarely been evaluated. The aim of the current study was to assess the impact of intraoperative transfusions on posttransplant outcomes. MATERIAL AND METHODS This retrospective cohort study was based on 229 HCC transplant recipients. The primary outcome measure was 5-year recurrence-free survival. Secondary outcome measures comprised overall and long-term survival at 5 years and 90-day mortality. Cox proportional hazard models and logistic regression were used to assess risk factors. RESULTS After adjustment for potential confounders, no association was found with respect to tumor recurrence for PRBCs (P=0.368) or FFP (P=0.081) transfusions. Similarly, PRBC transfusion (P=0.623) and FFP transfusion (P=0.460) had no impact on survival between 90 days and 5 years. PRBC transfusion increased the risk of 90-day mortality (P=0.005), while FFP transfusion was associated with a lower risk (P=0.036). CONCLUSIONS Intraoperative transfusions of blood products does not impair recurrence-free and long-term survival of patients with HCC undergoing liver transplantation. Intraoperative PRBC transfusion increases the risk of early mortality, whereas adequate supplementation of FFP plays a protective role.

摘要

背景

在接受肝移植的肝细胞癌 (HCC) 患者中,输注浓缩红细胞 (PRBC) 和新鲜冷冻血浆 (FFP) 的影响很少被评估。本研究的目的是评估术中输血对移植后结局的影响。

材料与方法

这是一项基于 229 例 HCC 移植受者的回顾性队列研究。主要观察指标为 5 年无复发生存率。次要观察指标包括 5 年总生存率和长期生存率以及 90 天死亡率。使用 Cox 比例风险模型和逻辑回归评估风险因素。

结果

在调整了潜在混杂因素后,PRBC(P=0.368)或 FFP(P=0.081)输血与肿瘤复发均无相关性。同样,PRBC 输血(P=0.623)和 FFP 输血(P=0.460)对 90 天至 5 年的生存没有影响。PRBC 输血增加了 90 天死亡率的风险(P=0.005),而 FFP 输血则降低了风险(P=0.036)。

结论

肝移植治疗 HCC 患者术中输血不会损害无复发生存率和长期生存率。术中 PRBC 输血增加了早期死亡率的风险,而适量补充 FFP 则起到保护作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验